GSK962040: A small molecule motilin receptor agonist which increases gastrointestinal motility in conscious dogs

Neurogastroenterology and Motility

Volumn 23, Issue 10, 2011, Pages

  Leming, S ^a   Broad, J ^b   Cozens, S J ^c   Otterson, M ^a   Winchester, W ^c   Lee, K ^c   Dukes, G E ^d   Sanger, G J ^b  

^a CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Dog; Erythromycin; GSK962040; Migrating motor complex; Motilin

Indexed keywords

GASTROINTESTINAL AGENT; GSK 962040; MOTILIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG EFFECT; FLUOROMETRY; GASTROINTESTINAL MOTILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MALE; MASS SPECTROMETRY; MOTOR PERFORMANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CONSCIOUSNESS; DOGS; GASTROINTESTINAL MOTILITY; HEK293 CELLS; HUMANS; MALE; PIPERAZINES; PIPERIDINES; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, NEUROPEPTIDE; TRANSFECTION;

EID: 80052859969     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2011.01770.x     Document Type: Article

References (25)

1. Sanger GJ, Alpers D. Development of drugs for gastrointestinal motor disorders: translating science to clinical need. Neurogastroenterol Motil 2008; 20: 177-84.
2. Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug insight: from disturbed motility to disordered movement - a review of the clinical benefits and medico-legal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 138-48.
3. Sanger GJ. Motilin, ghrelin and related neuropeptides as targets for the treatment of GI diseases. Drug Discov Today 2008; 13: 234-9.
4. Hawkyard CV, Koerner RJ. The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks. J Antimicrob Chemother 2007; 59: 347-58.
5. Zhou S, Chan E, Lim LY et al. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 2004; 5: 415-42.
6. Westaway SM, Sanger GJ. The identification and rationale for drugs which act at the motilin receptor. Prog Med Chem 2009; 48: 31-80.
7. McCallum RW, Cynshi O, US Investigative Team. Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi-center, placebo-controlled trial. Aliment Pharmacol Ther 2007, 26: 107-16.
8. Li JJ, Chao H-G, Wang H et al. Discovery of a potent and novel motilin agonist. J Med Chem 2004; 47: 1704-8.
9. Sanger GJ, Westaway SM, Barnes AA et al. GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterol Motil 2009; 21: 657-66.
10. Westaway SM, Brown SL, Fell SCF et al. Discovery of N-(3-Fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040): The first small molecule motilin receptor agonist clinical candidate. J Med Chem 2009; 52: 1180-9.
11. He J, Irwin DM, Chen R, Zhang Y. Stepwise loss of motilin and its specific receptor genes in rodents. J Mol Endocrinol 2010; 44: 37-44.
12. Sanger GJ, Holbrook JD, Andrews PLR. The translational value of rodent gastrointestinal functions: a cautionary tale. Trends Pharmacol Sci 2011; 32: 402-9.
13. Ohshiro H, Nonaka M, Ichikawa K. Molecular identification and characterization of the dog motilin receptor. Regul Pept 2008; 146: 80-7.
14. Otterson MF, Sarna SK, Moulder JE. Effects of fractionated doses of ionizing radiation on small intestinal motor activity. Gastroenterol 1988; 95: 1249-57.
15. Strunz U, Domschke W, Mitznegg P et al. Analysis of the motor effects of 13-norleucine motilin on the rabbit, guinea-pig, rat and human alimentary tract in vitro. Gastroenterology 1975; 68: 1485-91.
16. Bassil A, Murray C, Dass NM, Muir A, Sanger GJ. Prokineticin-2, motilin, ghrelin and metoclopramide: prokinetic utility in mouse stomach and colon. Eur J Pharmacol 2005; 524: 138-44.
17. Dass NB, Hill J, Muir A, Testa T, Wise A, Sanger GJ. The rabbit motilin receptor: molecular characterisation and pharmacology. Br J Pharmacol 2003; 140: 948-54.
18. 4 receptor function. J Pharm Pharmacol 1995; 47: 219-22.
19. Itoh Z, Nakaya M, Suzuki T, Arai H, Wakabayashi K. Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog. Am J Physiol 1984; 247: G688-94.
20. Otterson MF, Sarna SK. Gastrointestinal motor effects of erythromycin. Am J Physiol 1990; 259: G355-63.
21. Holle GE, Steinbach E, Forth W. Effects of erythromycin in the dog upper gastrointestinal tract. Am J Physiol 1992; 263: G52-9.
22. 3 receptor antagonism on erythromycin-induced canine intestinal motility disruption and emesis. Br J Pharmacol 1993; 108: 44-9.
23. Kaufman HS, Ahrendt SA, Pitt HA, Lillemoe KD. The effect of erythromycin on motility of the duodenum, sphincter of Oddi, and gallbladder in the prairie dog. Surgery 1993; 114: 543-8.
24. Chiba T, Thomforde GM, Kost LJ, Allen RG, Phillips SF. Motilides accelerate regional gastrointestinal transit in the dog. Aliment Pharmacol Ther 2000; 14: 955-60.
25. Tomomasa T, Kuroume T, Arai H, Wakabayashi K, Itoh Z. Erythromycin induces migrating motor complex in human gastrointestinal tract. Dig Dis Sci 1986; 31: 157-61.